COX-2 inhibition decreases VEGF expression and alveolar bone loss during the progression of experimental periodontitis in rats

Journal of Periodontology

Volumn 79, Issue 6, 2008, Pages 1062-1069

  Oliveira, Thais M ^a   Sakai, Vivien T ^a   Machado, Maria Aparecida A M ^a   Dionísio, Thiago J ^a   Cestari, Tania Mary ^a   Taga, Rumio ^a   Amaral, Sandra L ^b   Santos, Carlos F ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

Alveolar bone loss; Cyclooxygenase 2; Inflammation; Meloxicam; Periodontal disease; Vascular endothelial growth factor

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; MELOXICAM; MESSENGER RNA; THIAZINE DERIVATIVE; THIAZOLE DERIVATIVE; VASCULOTROPIN A;

ANIMAL; ARTICLE; BIOSYNTHESIS; DISEASE COURSE; DRUG ANTAGONISM; MALE; METABOLISM; NONPARAMETRIC TEST; OSTEOLYSIS; PATHOLOGY; PERIODONTITIS; RANDOMIZATION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; WISTAR RAT;

ALVEOLAR BONE LOSS; ANIMALS; BLOTTING, WESTERN; CYCLOOXYGENASE 2 INHIBITORS; DISEASE PROGRESSION; MALE; PERIODONTITIS; RANDOM ALLOCATION; RATS; RATS, WISTAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STATISTICS, NONPARAMETRIC; THIAZINES; THIAZOLES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 46049116341     PISSN: 00223492     EISSN: None     Source Type: Journal    
DOI: 10.1902/jop.2008.070411     Document Type: Article

References (46)

1. Armitage GC. Development of a classification system for periodontal diseases and conditions. Ann Periodontol 1999;4:1-6.
2. Horz HP, Conrads G. Diagnosis and anti-infective therapy of periodontitis. Expert Rev Anti Infect Ther 2007;5:703-715.
3. Kantarci A, Van Dyke TE. Resolution of inflammation in periodontitis. J Periodontol 2005;76(11 Suppl.)2168-2174.
4. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340:448-454.
5. Bezerra MM, de Lima V, Alencar VB, et al. Selective cyclooxygenase-2 inhibition prevents alveolar bone loss in experimental periodontitis in rats. J Periodontol 2000;71:1009-1014.
6. Curtis EK. Inflammatory response. J Mass Dent Soc 2005;54:48.
7. Koj A. Initiation of acute phase response and synthesis of cytokines. Biochim Biophys Acta 1996;1317:84-94.
8. Hanada T, Yoshimura A. Regulation of cytokine signaling and inflammation. Cytokine Growth Factor Rev 2002;13:413-421.
9. Mariotti A. Sex steroid hormones and cell dynamics in the periodontium. Crit Rev Oral Biol Med 1994;5:27-53.
10. Werner S, Grose R. Regulation of wound healing by growth factors and cytokines. Physiol Rev 2003;83:835-870.
11. Oberyszyn TM. Inflammation and wound healing. Front Biosci 2007;12:2993-2999.
12. Madianos PN, Bobetsis YA, Kinane DF. Generation of inflammatory stimuli: How bacteria set up inflammatory responses in the gingiva. J Clin Periodontol 2005; 32(Suppl. 6):57-71.
13. McCourt P. Genetic analysis of hormone signaling. Annu Rev Plant Physiol Plant Mol Biol 1999;50:219-243.
14. Booth V, Young S, Cruchley A, Taichman NS, Paleolog E. Vascular endothelial growth factor in human periodontal disease. J Periodontal Res 1998;33:491-499.
15. Johnson RB, Serio FG, Dai X. Vascular endothelial growth factors and progression of periodontal diseases. J Periodontol 1999;70:848-852.
16. Suthin K, Matsushita K, Machigashira M, et al. Enhanced expression of vascular endothelial growth factor by periodontal pathogens in gingival fibroblasts. J Periodontal Res 2003;38:90-96.
17. Cetinkaya BO, Keles GC, Ayas B, Sakallioglu EE, Acikgoz G. The expression of vascular endothelial growth factor in a rat model at destruction and healing stages of periodontal disease. J Periodontol 2007;78:1129-1135.
18. Lee E, Yang YH, Ho YP, Ho KY, Tsai CC. Potential role of vascular endothelial growth factor, interleukin-8 and monocyte chemoattractant protein-1 in periodontal diseases. Kaohsiung J Med Sci 2003;19:406-415.
19. Prapulla DV, Sujatha PB, Pradeep AR. Gingival crevicular fluid VEGF levels in periodontal health and disease. J Periodontol 2007;78:1783-1787.
20. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-676.
21. Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J Mol Med 1999; 77:527-543.
22. Ferrara N. The role of VEGF in the regulation of physiological and pathological angiogenesis. EXS 2005; 94:209-231.
23. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999;13:9-22.
24. Yamazaki Y, Morita T. Molecular and functional diversity of vascular endothelial growth factors. Mol Divers 2006;10:515-527.
25. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002;2:795-803.
26. Morton RS, Dongari-Bagtzoglou AI. Cyclooxygenase-2 is upregulated in inflamed gingival tissues. J Periodontol 2001;72:461-469.
27. Gurgel BC, Duarte PM, Nociti FH Jr., et al. Impact of an anti-inflammatory therapy and its withdrawal on the progression of experimental periodontitis in rats. J Periodontol 2004;75:1613-1618.
28. Nassar CA, Nassar PO, Nassar PM, Spolidorio LC. Selective cyclooxygenase-2 inhibition prevents bone resorption. Braz Oral Res 2005;19:36-40.
29. Gallo O, Franchi A, Magnelli L, et al. Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis. Neoplasia 2001;3:53-61.
30. Pai R, Szabo IL, Soreghan BA, Atay S, Kawanaka H, Tarnawski AS. PGE(2) stimulates VEGF expression in endothelial cells via ERK2/JNK1 signaling pathways. Biochem Biophys Res Commun 2001;286:923-928.
31. Lohinai Z, Benedek P, Fehér E, et al. Protective effects of mercaptoethylguanidine, a selective inhibitor of inducible nitric oxide synthase, in ligature-induced periodontitis in the rat. Br J Pharmacol 1998;123: 353-360.
32. Di Paola R, Marzocco S, Mazzon E, et al. Effect of aminoguanidine in ligature-induced periodontitis in rats. J Dent Res 2004;83:343-348.
33. Györfi A, Fazekas A, Suba Z, Ender F, Rosivall L. Neurogenic component in ligature-induced periodontitis in the rat. J Clin Periodontol 1994;21:601-605.
34. Leitão RF, Rocha FA, Chaves HV, et al. Locally applied isosorbide decreases bone resorption in experimental periodontitis in rats. J Periodontol 2004;75: 1227-1232.
35. Santos CF, Oliveira EB, Salgado MC, Greene AS. Molecular cloning and sequencing of the cDNA for rat mesenteric arterial bed elastase-2, an angiotensin II-forming enzyme. J Cardiovasc Pharmacol 2002;39: 628-635.
36. Santos CF, Caprio MA, Oliveira EB, et al. Functional role, cellular source, and tissue distribution of rat elastase-2, an angiotensin II-forming enzyme. Am J Physiol Heart Circ Physiol 2003;285:H775-H783.
37. Becari C, Sivieri DO Jr., Santos CF, Moyses MK, Oliveira EB, Salgado MC. Role of elastase-2 as an angiotensin II-forming enzyme in rat carotid artery. J Cardiovasc Pharmacol 2005;46:498-504.
38. Amaral SL, Papanek PE, Greene AS. Angiotensin II and VEGF are involved in angiogenesis induced by short-term exercise training. Am J Physiol Heart Circ Physiol 2001;281:H1163-H1169.
39. Tsokos M, Pufe T, Paulsen F, Anders S, Mentlein R. Pulmonary expression of vascular endothelial growth factor in sepsis. Arch Pathol Lab Med 2003;127:331-335.
40. Monacci WT, Merrill MJ, Oldfield EH. Expression of vascular permeability factor/vascular endothelial growth factor in normal rat tissues. Am J Physiol 1993;264: C995-C1002.
41. Lohinai Z, Stachlewitz R, Szekely AD, Feher E, Dezsi L, Szabo C. Evidence for the expression of cyclooxygenase-2 enzyme in periodontitis. Life Sci 2001;70:279-290.
42. Zhang ZH, Wei SG, Francis J, Felder RB. Cardiovascular and renal sympathetic activation by blood-borne TNF-alpha in rat: The role of central prostaglandins. Am J Physiol Regul Integr Comp Physiol 2003; 284:R916-R927.
43. Engelhardt G. Pharmacology of meloxicam, a new non-steroidal anti-inflammatory drug with an improved safety profile through preferential inhibition of COX-2. Br J Rheumatol 1996;35(Suppl. 1):4-12.
44. Jouzeau JY, Terlain B, Abid A, Nédélec E, Netter P. Cyclooxygenase isoenzymes. How recent findings affect thinking about nonsteroidal anti-inflammatory drugs. Drugs 1997;53:563-582.
45. Neufeld G, Lange T, Varshavsky A, Kessler O. Semaphorin signaling in vascular and tumor biology. Adv Exp Med Biol 2007;600:118-131.
46. Deprimo SE, Bello CL, Smeraglia J, et al. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: Modulation of VEGF and VEGF-related proteins. J Transl Med 2007;5:32.